Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr:68:109518.
doi: 10.1016/j.cellsig.2019.109518. Epub 2019 Dec 24.

Apoptosis and autophagy in polycystic kidney disease (PKD)

Kristen L Nowak  1 , Charles L Edelstein  2
Affiliations
Review

Apoptosis and autophagy in polycystic kidney disease (PKD)

Kristen L Nowak et al. Cell Signal. 2020 Apr.

Abstract

Apoptosis in the cystic epithelium is observed in most rodent models of polycystic kidney disease (PKD) and in human autosomal dominant PKD (ADPKD). Apoptosis inhibition decreases cyst growth, whereas induction of apoptosis in the kidney of Bcl-2 deficient mice increases proliferation of the tubular epithelium and subsequent cyst formation. However, alternative evidence indicates that both induction of apoptosis as well as increased overall rates of apoptosis are associated with decreased cyst growth. Autophagic flux is suppressed in cell, zebra fish and mouse models of PKD and suppressed autophagy is known to be associated with increased apoptosis. There may be a link between apoptosis and autophagy in PKD. The mammalian target of rapamycin (mTOR), B-cell lymphoma 2 (Bcl-2) and caspase pathways that are known to be dysregulated in PKD, are also known to regulate both autophagy and apoptosis. Induction of autophagy in cell and zebrafish models of PKD results in suppression of apoptosis and reduced cyst growth supporting the hypothesis autophagy induction may have a therapeutic role in decreasing cyst growth, perhaps by decreasing apoptosis and proliferation in PKD. Future research is needed to evaluate the effects of direct autophagy inducers on apoptosis in rodent PKD models, as well as the cause and effect relationship between autophagy, apoptosis and cyst growth in PKD.

Keywords: Apoptosis; Autophagy; Polycystic kidney disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Molecular pathways involved in PKD, autophagy and apoptosis. Autophagy and apoptosis are intimately related. Pathways known to be activated in PKD are shown in red. The mTOR pathway that inhibits autophagy is activated in PKD [28]. There is cross talk between mTOR pathway of autophagy and the apoptosis pathways [129]. Bcl-2 is a central regulator of autophagy and apoptosis and functions by interacting with Beclin-1 and inhibiting autophagy. The pro-apoptotic mitochondrial protein, Bad, disrupts the interaction between Bcl-2 and Beclin-1 to induce autophagy. The pro-apoptotic protein, PUMA, a p53-inducible BH3-only protein, triggers mitochondrial-specific autophagy. Activation of caspase-3 and dysregulation of the balance between pro- and anti-apoptotic Bcl-2 family members, specifically a down-regulation of anti-apoptotic Bcl-xL, has been shown in PKD [9] and Bcl-2 downregulation worsens PKD [10]. Caspases activated during apoptosis can cleave and inactivate Beclin-1. Ambra-1, a key molecule that promotes the initial steps of autophagy, is irreversibly cleaved by both calpains and caspases. During apoptosis, Atg3 is cleaved by caspase 8 and cleaved Atg3 inhibits autophagy. Autophagy is inhibited by caspase-8-mediated cleavage of Beclin-1 [174]. The intrinsic and extrinsic pathways of caspase activation in apoptosis are activated in PKD [51]. In addition to the role that apoptosis-related proteins play in modulating autophagy, many autophagic proteins can induce apoptosis. mTOR forms a complex with PRAS40 and PRR5-like proteins to induce apoptosis. Activation of AMPK is known to inhibit mTOR and induce autophagy. AMPK activation with metformin is protective in PKD [152] but the effect of metformin on autophagy and apoptosis in PKD is not known. Atg12 increases mitochondrial apoptosis by directly binding to and inactivating Bcl-2. PKD mice have a significantly lower renal mRNA expression of Atg12 and other autophagy-related genes, Atg3, beclin1 and p62, [18]. Abbreviations: B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), p53 upregulated modulator of apoptosis (PUMA), proline-rich Akt substrate of 40 kDa (PRAS40), PRoline-Rich protein 5 (PRR5), activating molecule in Beclin1-regulated autophagy protein-1 (Ambra-1), 5’ AMP-activated protein kinase (AMPK).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fick GM, Gabow PA, Natural history of autosomal dominant polycystic kidney disease, Annu. Rev. Med 45 (1994) 23–29. - PubMed
    1. Wilson PD, Polycystic kidney disease N. Engl. J. Med 350 (2) (2004) 151–164. - PubMed
    1. Antignac C, Calvet JP, Germino GG, Grantham JJ, Guay-Woodford LM, Harris PC, Hildebrandt F, Peters DJ, Somlo S, Torres VE, et al., The future of polycystic kidney disease research-as seen by the 12 Kaplan Awardees, J. Am. Soc. Nephrol 26 (9) (2015. September) 2081–2095. - PMC - PubMed
    1. Belibi FA, Edelstein CL, Novel targets for the treatment of autosomal dominant polycystic kidney disease, Expert Opin. Investig. Drugs 19 (3) (2010) 315–328. - PMC - PubMed
    1. Torres VE, Harris PC, Autosomal dominant polycystic kidney disease: the last 3 years, Kidney Int. 76 (2) (2009) 149–168. - PMC - PubMed

Publication types

LinkOut - more resources